The safety of rofecoxib (Q28176535)

Expert Opinion on Drug Safety

Europe PubMed Central

title

The safety of rofecoxib (English)

0 references

author name string

Michel Burnier

series ordinal

1

0 references

language of work or name

English

0 references

publication date

May 2005

0 references

published in

0 references

volume

4

0 references

issue

3

0 references

page(s)

491-9

0 references

cites work

Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

Upper gastrointestinal adverse drug reactions and cyclo-oxygenase-2 inhibitors (celecoxib and rofecoxib): a case/non-case study from the French Pharmacovigilance Database

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

Safety of a cyclooxygenase-2 inhibitor in patients with aspirin-sensitive asthma

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

Nonsteroidal anti-inflammatory drug use and acute myocardial infarction

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

Selective COX-2 inhibition improves endothelial function in coronary artery disease

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

Selective cyclo-oxygenase-2 inhibition with parecoxib acutely impairs endothelium-dependent vasodilatation in patients with essential hypertension

21 April 2017

1 reference

https://api.crossref.org/works/10.1517/14740338.4.3.491

The coxibs, selective inhibitors of cyclooxygenase-2.

21 April 2017

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Cyclooxygenases, the kidney, and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Risk of cardiovascular events and rofecoxib: cumulative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Risk of cardiovascular events associated with selective COX-2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Safety of the new selective cyclooxygenase type 2 inhibitors rofecoxib and celecoxib in patients with anaphylactoid reactions to nonsteroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Renal effects of COX-2-selective inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

A comparison of adverse renovascular experiences among osteoarthritis patients treated with rofecoxib and comparator non-selective non-steroidal anti-inflammatory agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Cyclo-oxygenase-2 inhibition increases blood pressure in rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Relationship between COX-2 specific inhibitors and hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Association between naproxen use and protection against acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflammatory drugs (ibuprofen, diclofenac, and nabumetone).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491

Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14740338.4.3.491